Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material

NCT: NCT07276711 · RECRUITING

NCT IDNCT07276711
StatusRECRUITING
Start Date2026-05-12
Completion2028-05

Brief Summary

The objective of this study is to demonstrate safety and efficacy of the EmStop Embolic Protection System when used as indicated to capture and remove thrombus/debris during self-expanding transcatheter aortic valve replacement (TAVR) procedures.

Frequently Asked Questions

What is CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material?

CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material is a clinical trial registered under NCT07276711. Current status: RECRUITING.

What is the status of NCT07276711?

The current status of NCT07276711 (CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material) is: RECRUITING.

When did CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material start?

CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material started on 2026-05-12.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑